Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02616 CSTONE PHARMA-B
RTNominal down9.270 -0.830 (-8.218%)
Others

15/09/2021 15:53

CStone Pharma (02616) gets IND application approval

[ET Net News Agency, 15 September 2021] CStone Pharmaceuticals (02616) said the
investigational new drug (IND) application of multi-specific antibody CS2006/NM21-1480 has
been approved by the National Medical Products Administration (NMPA) of China.
CS2006/NM21-1480 represents a leading class of next-generation anti-PD-1/PD-L1 cancer
immunotherapies and a new backbone molecule for combinations. It is a monovalent,
tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin
(HSA).(RC)

Remark: Real time quote last updated: 06/12/2021 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.